Attached files
| file | filename |
|---|---|
| EX-31.1 - EXHIBIT 31.1 - Sio Gene Therapies Inc. | axovantexhibit311.htm |
| 10-K - 10-K - Sio Gene Therapies Inc. | axovant3312010k.htm |
| EX-32.2 - EXHIBIT 32.2 - Sio Gene Therapies Inc. | axovantexhibit322.htm |
| EX-31.2 - EXHIBIT 31.2 - Sio Gene Therapies Inc. | axovantexhibit312.htm |
| EX-23.1 - EXHIBIT 23.1 - Sio Gene Therapies Inc. | axovantexhibit231.htm |
| EX-21.1 - EXHIBIT 21.1 - Sio Gene Therapies Inc. | axovantexhibit211.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report on Form 10-K of Axovant Gene Therapies Ltd. (the “Company”) for the fiscal year ended March 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Pavan Cheruvu, Principal Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
(1)the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: June 9, 2020 | By: | /s/ Pavan Cheruvu |
Pavan Cheruvu | ||
Principal Executive Officer | ||
This certification accompanies the Report, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Report), regardless of any general incorporation language contained in such filing.